论文部分内容阅读
Despite concerns regarding the long-term safety of drug-eluting stent(DES) implantation because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is unknown. We investigated the incidence, risk factors, and association of antiplatelet therapy interruption for the development of stent thrombosis after DES implantation during long-term follow-up. A total of 1,911 consecutive patients with DES implantation were enrolled(sirolimus-eluting stents in 1,545 patients, 2,045 lesions; paclitaxel-eluting stents in 366 patients, 563 lesions). During long-term follow-up(median 19.4 months, interquartile range 15.3 to 24.3), 15 patients(0.8%, 95%confidence interval 0.5%to 1.3%) developed stent thrombosis within 6 hours to 20.4 months. Eleven patients(0.6%, 95%confidence interval 0.3%to 1.0%) had late thrombosis(median 6.1 months). The incidence of stent thrombosis was 3.3%(4 of 121 patients) in patients with complete interruption of antiplatelet therapy(vs 0.6%in those without, p=0.004) and 7.8%(5 of 64 patients) with premature interruption of aspirin or clopidogrel, or both(vs 0.5%in those without, p< 0.001). Independent predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length. Stent thrombosis also developed while patients were on dual antiplatelet therapy(all patients with acute/subacute stent thrombosis and 36%of those with late stent thrombosis; 47%of total with stent thrombosis). In conclusion, stent thrombosis occurred in 0.8%after DES implantation during long-term follow-up. The incidence of late stent thrombosis was 0.6%, similar to that for bare metal stents. The predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length.
Despite concerns regarding the long-term safety of drug-eluting stent (DES) implantation because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is unknown. We investigated the incidence, risk factors, and association of antiplatelet therapy interruption for the development of stent thrombosis after DES implantation during long-term follow-up. A total of 1,911 consecutive patients with en implantation of enrolled (sirolimus-eluting stents in 1,545 patients, 2,045 lesions; paclitaxel-eluting stents in 366 patients, 563 During long-term follow-up (median 19.4 months, interquartile range 15.3 to 24.3), 15 patients (0.8%, 95% confidence interval 0.5% to 1.3%) developed stent thrombosis within 6 hours to 20.4 months. The incidence of stent thrombosis was 3.3% (4 of 121 patients) in patients with complete interruption of antiplatelet therapy (vs 0.6% in (0.6%, 95% confidence interval 0.3% to 1.0%) had late thrombosisthose without, p = 0.004) and 7.8% (5 of 64 patients) with premature interruption of aspirin or clopidogrel, or both (vs 0.5% in those without, p <0.001). Independent predictors of stent thrombosis were premature antiplatelet therapy interruption, Primary stenting in acute myocardial infarction, and total stent length. Stent thrombosis also developed while patients were on dual antiplatelet therapy (all patients with acute / subacute stent thrombosis and 36% of those with late stent thrombosis; 47% of total with stent thrombosis) In conclusion, stent thrombosis occurred in 0.8% after DES implantation during long-term follow-up. The incidence of late stent thrombosis was 0.6%, similar to that for bare metal stents. The predictors of stent thrombosis were premature antiplatelet therapy interruption, primary stenting in acute myocardial infarction, and total stent length.